Gongwin Biopharm Holdings (Gongwin-KY) announced that its preliminary consolidated revenue for August reached NT$4.31 million, marking a month-on-month increase of 53.65% and a year-on-year rise of 35.71%, setting a record high for a single month. The growth was primarily driven by the expanded market penetration of its new drug PTS302 (ProSian) for severe central airway obstruction (MAO) in lung cancer in China, with shipment volumes continuing to rise.

General Manager Lin Mao-Yuan highlighted that lung cancer remains the leading cause of cancer incidence and mortality in China, with approximately 30% of patients developing MAO. Coupled with the annual increase in new lung cancer cases, there is an urgent demand for new therapeutic options. Recently, PTS302 passed the preliminary review for inclusion in China’s 2025 National Basic Medical Insurance Drug List and has entered the subsequent evaluation phase. It is also among the few drugs simultaneously passing preliminary review for inclusion in commercial insurance innovative drug catalogs. If successfully incorporated into both insurance “dual catalogs,” hospital usage is expected to increase four- to sixfold, significantly expanding revenue potential.

In addition, to further strengthen its presence in the Chinese market and enhance the drug’s economic value, Gongwin is accelerating the development of PTS302 for new indications. A multi-center Phase III clinical trial is planned for the treatment of malignant pleural effusion, with patient enrollment expected to take place simultaneously in China, the United States, Taiwan, and Malaysia. Initial implementation has already begun at the First Affiliated Hospital of Guangzhou Medical University.

For August, consolidated revenue totaled NT$4.31 million, a month-on-month increase of 53.65% and a year-on-year increase of 35.71%, setting a record high for a single month. Cumulative revenue for the first eight months reached NT$23.49 million, also a record for the same period, up 11.03% year-on-year. When measured in functional currency USD, both August and cumulative revenue growth rates exceeded those calculated in New Taiwan Dollars.

Resource: 共信-KY新藥中國市場滲透率增，8月營收跳，推動PTS302擴增新適應症